Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to...
Vous n'êtes pas connecté
A revolutionary personalized cancer vaccine developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology is expected to receive regulatory approval by August, potentially allowing treatments to commence as early as September, according to the institute’s director, Alexander Gintsburg. This breakthrough marks a significant milestone in the global fight against cancer, leveraging advanced mRNA technology […]
Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to...
AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine...
Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the...
The Central Drug Standards Control Organization (CDSCO) has granted a license to Biolumpivaxin, India’s first vaccine against lumpy skin disease...
Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the...
Scientists from the German Cancer Research Center (DKFZ) and ShanghaiTech University have developed an innovative method for growing brain tumors of...
TUESDAY, Feb. 18, 2025 -- The U.S. Department of Agriculture (USDA) has granted conditional approval for a new bird flu vaccine for poultry.This new...
In a breakthrough moment for Africa’s vaccine independence, two landmark deals could help put the continent on a path to becoming a producer, not...
THURSDAY, Feb. 6, 2025 -- Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell...
Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein...